Leadership

Our leadership, which includes our executive management and board of directors is accountable for the success and continued innovation at Horizon

Executive Management

Terry Pizzie - Chief Executive Officer

Terry Pizzie - CEOTerry became Chief Executive Officer in May 2018 having joined Horizon Discovery Group in February 2017 as Head of Commercial Operations. He has amassed more than 30 years of commercial experience within the biotechnology tools sector. He started his career with Applied Biosystems in 1988 in a sales role and became Vice President of Europe in 2003. Terry went on to join the Swedish biotechnology firm Biacore in 2005 as SVP Global Commercial Operations and was part of the team that reignited the company’s commercial success, culminating in its acquisition by GE Life Sciences. After a period with Genetix PLC as Director, Global Commercial Operations prior to its acquisition by Danaher, Terry went on to head global sales at Pacific Biosciences.

Terry graduated with a degree in Physiology and Biochemistry from the University of Reading and since then has spent most of his working life focused upon commercial excellence within the sector.

Jayesh Pankhania - Chief Financial Officer

Jayesh Pankhania - CFOJayesh joined Horizon as CFO in January 2019 and had previously been Interim CFO leading the transformation of the finance function and the development of Horizon’s strategy. He holds an MBA from the London Business School, a degree in Accountancy from the University of East Anglia and is a Chartered Accountant with over 25 years senior finance experience.

Jayesh’s experience includes senior CFO roles at FTSE listed businesses such as Asia Resource Minerals plc, Serco plc and Carillion plc where he led businesses through M&A, implementation of strong corporate and finance governance and development and execution of corporate strategies. In addition, he has led smaller entrepreneurial businesses such as the UK property business of Hines, a real estate developer and Xtera Limited, a provider of subsea telecoms technology. Jayesh qualified with PriceWaterhouseCoopers.

Jayesh is Founder and Director of Nisaba Limited and is a Trustee of Ealing Mencap.

Gabe Longoria - Head of Global Commercial

Gabe LongoriaGabe was appointed Global Head of Commercial in January 2019 and is responsible for leading and managing all commercial operations of the business to ensure that profitable business growth is accelerated, and commercial success is achieved. He joined Horizon Discovery in April 2017 as VP Global Sales and Key Accounts, and was formerly Director of Sales of the Bioproduction and Drug Discovery Divisions of Molecular Devices, a subsidiary of Danaher Corp. He has more than 25 years’ commercial experience in Cell Biology, Biotherapeutics and Drug Discovery, encompassing various sales, marketing, and product management roles with Leica Microsystems, Genetix, and Ventana Medical Systems, a member of the Roche Group. He has a degree in microbiology from the University of Arizona.

Kim Nichols - Head of Global Ops

Kim NicholsKim joined Horizon Discovery in 2017 with the acquisition of Dharmacon. Kim has been with the Dharmacon business for 18 years in various operational roles under Thermo Fisher Scientific and GE Healthcare.

Prior to joining Dharmacon, Kim spent almost 10 years at the University of Iowa researching and mapping inherited eye diseases. Kim has degrees in Genetics and Business Administration.

Dr Chris Lowe - Head of Research Operations

Chris LoweChris joined Horizon Discovery in 2011 and, prior to leading all research operations within Horizon, led the scientific teams responsible for the development and provision of a range of translational research services to support pre-clinical drug discovery programs. Chris has a background in the genetic analysis of complex disease having obtained his PhD in the field of Medical Genetics from the University of Cambridge where he engaged in research into the genetic causes of Type 1 diabetes in the laboratory of Prof. John Todd, followed by postdoctoral work focusing on Type 2 diabetes and metabolic disease in the laboratory of Prof. Stephen O’Rahilly. 

Julie Cormack - Global Head of HR

Julie CormackJulie is an experienced commercially minded HR Director who has operated for over 20 years in global roles across a wide range of industries. Having worked in both large corporations such as Maersk and BP, and then moving into the private equity world. She has extensive experience of helping organizations with their People Strategies in high growth environments. Julie graduated from Birmingham University with a degree in Ancient History and Archaeology and then after living in Japan for 10 years also embarked upon a Masters in Japanese. She is a also a Chartered Fellow of the Institute of Personnel Development.

Brian Burke - Global Head of Strategy

Brian BurkeBrian joined Horizon in August 2012 as a Business Development Manager and was promoted to Global Head of Strategy during 2018. In this role, he is responsible for driving strategic development and execution across the Horizon business. He works closely with other functions to analyse and impact the wider Horizon opportunity in order to build value more effectively.

Before joining Horizon, Brian worked successfully in a number of commercial and licensing roles with a particular focus on gene editing, bioproduction and next generation sequencing. Prior to moving to industry, he gained a first class honor degree from the University of Glasgow and a PhD from Leeds University.

Paul Brooks - Head of Business Operations

Paul BrooksPaul has over 20 years of experience in leading the successful development and commercialization of tools and services for academic, pharmaceutical, biotech, biopharma and molecular diagnostic markets.

He has held senior leadership positions in the USA and the UK, including Chief Commercial Officer and Executive Board member of Oxford Genetics, where he was responsible for developing and leading their commercial strategy when entering the CRISPR gene editing and Cell and Gene Therapy markets; Head of Discovery Services at Sigma-Aldrich, where he drove strategic transformation of the Pharmaceutical Research business unit to create a global leading product and service portfolio for drug discovery research; and Global Marketing Manager at Sigma-Aldrich, where he led product management teams in the development and commercialization of functional genomic technologies, including the world’s first commercial gene editing technology and custom cell line engineering service.

Paul has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA with a focus on Commercializing Biotechnology from the University of Nottingham Business School.

Board of Directors - Internal

Terry Pizzie - Chief Executive Officer

Terry Pizzie - CEOTerry became Chief Executive Officer in May 2018 having joined Horizon Discovery Group in February 2017 as Head of Commercial Operations. He has amassed more than 30 years of commercial experience within the biotechnology tools sector. He started his career with Applied Biosystems in 1988 in a sales role and became Vice President of Europe in 2003. Terry went on to join the Swedish biotechnology firm Biacore in 2005 as SVP Global Commercial Operations and was part of the team that reignited the company’s commercial success, culminating in its acquisition by GE Life Sciences. After a period with Genetix PLC as Director, Global Commercial Operations prior to its acquisition by Danaher, Terry went on to head global sales at Pacific Biosciences.

Terry graduated with a degree in Physiology and Biochemistry from the University of Reading and since then has spent most of his working life focused upon commercial excellence within the sector.

Jayesh Pankhania - Chief Financial Officer

Jayesh Pankhania - CFOJayesh joined Horizon as CFO in January 2019 and had previously been Interim CFO leading the transformation of the finance function and the development of Horizon’s strategy. He holds an MBA from the London Business School, a degree in Accountancy from the University of East Anglia and is a Chartered Accountant with over 25 years senior finance experience.

Jayesh’s experience includes senior CFO roles at FTSE listed businesses such as Asia Resource Minerals plc, Serco plc and Carillion plc where he led businesses through M&A, implementation of strong corporate and finance governance and development and execution of corporate strategies. In addition, he has led smaller entrepreneurial businesses such as the UK property business of Hines, a real estate developer and Xtera Limited, a provider of subsea telecoms technology. Jayesh qualified with PriceWaterhouseCoopers.

Jayesh is Founder and Director of Nisaba Limited and is a Trustee of Ealing Mencap.

Board of Directors - External appointees

Dr Ian Gilham - Non-Executive Chairman

Ian GilhamIan is currently Non-Executive Chairman of Genedrive plc, a developer of innovative molecular diagnostic systems and Biosurfit SA which is focused on the development and commercialization of point-of-care diagnostics. Ian also serves as non-executive Chairman of Elucigene plc. Ian has previously been Chief Executive Officer of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.

Mrs Susan Searle - Non-Executive Director

Susan SearleSusan has over 20 years’ commercial experience as an entrepreneur and innovator. She co-founded Imperial Innovations Group Plc (now part of IP Group Plc),a leading technology venture investment businesses, leading as CEO from 2002 to 2013. During this time the company invested over £120 million, the majority of which was in biotech companies. Susan also holds non-executive director positions with Woodford Patient Capital plc (chair), Mercia Technologies plc (chair), Benchmark Holdings plc (chair of the Remuneration Committee), and QinetiQ Group plc (Audit, Risk and Remuneration Committees). Susan acts as the Senior Independent Director on Horizon’s Board.

Susan has previously held commercial roles with Shell Chemicals, Montech PTY Ltd, and the Bank of Nova Scotia. She has a degree in chemistry from Oxford University.

Dr Susan Galbraith - Non-Executive Director

Dr Susan GalbraithDr. Susan Galbraith, currently Senior Vice President and Head of Oncology Innovative Medicines at AstraZeneca, trained as a clinical oncologist, after studying medicine at Manchester and Cambridge Universities, and joins with over 20 years’ combined academic and industry experience.

Susan was previously at Bristol-Myers Squibb, where she was Vice President of Oncology and Clinical Biomarkers from 2008 to 2010. In her roles at both Bristol- Myers Squibb and AstraZeneca, Susan has successfully developed and delivered strategies for the oncology and biomarker groups, resulting in increased success rates, enhanced scientific reputation and high value collaborations. She has also delivered major reorganizations, redesigned governance processes, and contributed to discussions on drug and diagnostic development with regulatory agencies in North America and Europe.

Dr Vishal Gulati - Non-Executive Director

Dr Vishal GulatiDr. Vishal Gulati is a specialist healthcare investor in diagnostics, digital healthcare and biotechnology and has served on the boards of companies across Europe, the USA and in India for over a decade. Vishal gained investment management and industry experience at Draper Esprit (formerly DFJ Esprit), Atlas Venture, the Wellcome Trust. Having been a practicing physician prior to that, Vishal is able to combine the insights from a technical as well as a financial perspective.

Vishal qualified in medicine in India and received his postgraduate training in Oxford and London as a Rhodes Scholar. In addition to several company boards, Vishal has served on the BioCatalyst awards committee (a UK Government backed £180 million fund for emerging technology companies) an advisor to the Mayor of London’s health commission.

Mr Grahame Cook - Non-Executive Director

Mr Grahame CookGrahame is an experienced FTSE and AIM non-executive, with extensive experience as an audit committee chairman. With a background in banking,where he has specialized in the life sciences, pharma and biotech sectors, Grahame has over 20 years’ experience of M&A, equity capital markets and investor relations.Grahame started his career at Arthur Andersen, where he qualified as a chartered accountant and worked within audit and corporate investigations. Subsequent positions include UBS, where he was a member of the global investment banking management committee and global head of equity advisory, and WestLB Panmure, where he was joint Chief Executive Officer. Grahame currently sits on a number of boards, chairing four, including Sinclair Pharma plc and Morphogenesis Inc.Grahame is a graduate of the University of Oxford and remains a member of the ICAEW.

Margarita Krivitski - Non-Executive Director

Margarita KrivitskiMargarita Krivitski is a Vice President at ValueAct Capital. Prior to joining ValueAct Capital in 2015, Margarita worked at TPG Capital in the North American Buyout Group focused on healthcare investments. Prior to TPG Capital, Margarita was an investment banker at Goldman Sachs. She received her B.A. in Applied Mathematics from Harvard University.

Margarita brings experience in finance, strategy, mergers and acquisitions as well as deep knowledge of the Horizon Discovery business.